When was Trinomab founded?

Trinomab was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is Trinomab located?

Trinomab is headquartered in Zhuhai, China.

Is Trinomab a funded company?

Trinomab is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Apr 27, 2021.

When was the latest funding round of Trinomab?

Trinomab's latest funding was a $***** Series A round on Apr 27, 2021, with participation from 2 investors. Its primary sector is Immunotherapy. In China, the Immunotherapy sector has seen $359M in funding in 2026 to date.

Where does Trinomab rank among its competitors?

Trinomab ranks 386th amongst 2134 active competitors, of which 154 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Trinomab?

Trinomab's top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Trinomab - 2026 Company Profile, Team, Funding & Competitors

Trinomab is a series A company based in Zhuhai (China), founded in 2015. It operates as a Developer of immunotherapeutics for multiple diseases. Trinomab has raised $69.3M in funding from GL Ventures and Hillhouse. The company has 2134 active competitors, including 154 funded and 267 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.

Company Details

Website: www.trinomab.com/
Email ID: *****@trinomab.com
Phone Number: +86 **********

Key Metrics

Founded Year

2015

Location

Zhuhai, China

Stage

Series A

Total Funding

$69.3M in 1 round

Latest Funding Round

Series A, Apr 27, 2021, $*****

Investors

GL Ventures & 2 more

Ranked

386^th among 2134 active competitors

Similar Companies

argenx & 234 more

View Trinomab's full profile

Trinomab has raised a total funding of $69.3M over 1 round. Its latest funding round was a Series A round on Apr 27, 2021 for $*****. 2 investors participated in its latest round. Trinomab has 3 institutional investors.

Here is the list of recent funding rounds of Trinomab:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 27, 2021	2282857	Series A	9097212	1780916	9221349	9429222

Access funding benchmarks and valuations. Sign up today!

View details of Trinomab's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Trinomab include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Trinomab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
7th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
8th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	66/100
9th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	71/100
10th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
386th	Trinomab 2015, Zhuhai (China), Series A	Developer of immunotherapeutics for multiple diseases	$69.3M	RiverHead Capital, Hillhouse & 1 others	30/100